Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue includes updates on what will come next for the AIDS vaccine regimen that showed modest efficacy in the trial known as RV144; the recent VOICE trial modification; progress in demonstration projects, public health guidance and regulatory decision-making around PrEP in the United States; and, a table of early-phase studies of ARV-based prevention strategies for HIV-negative people.
Px Wire October-December 2011, Vol. 4, No. 4
Px Wire October-December 2010, Vol. 3, No. 4
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue include an update of the ongoing discussions around the follow-up of the CAPRISA 004 trial finding that 1% tenofovir gel reduces a women’s risk of acquiring HIV by 39 percent overall and asks follow-up questions. What additional trials are being considered and why? Who will map the next steps? This issue also touches on the increasing discussions of “treatment as prevention” in reference to the possible use of antiretroviral treatment to reduce the risk of HIV transmission.
We can use it if it’s made for us: Kenyan Sex workers perspectives and Voices on Microbicides and PrEP
This report gathers perceptions and concerns from female sex works in Kenya concerning access to microbicides and PrEP. It highlights the importance of engaging this key population in product research and development.
Px Wire April-June 2009, Vol. 2, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue features multiple trial updates, including a review of the key findings from a trial of HSV-2 suppression. The issue also features a discussion of the results of the HPTN 035 microbicide trial (which tested PRO 2000 and BufferGel) and preparations for the upcoming results of MDP 301, also testing PRO 2000 gel. Additionally, this issue provides information on new trials including HVTN 505 (described in this year’s first issue of Px Wire), which began screening participants in June, a new trial on intermittent PrEP scheduled to begin in July, and research to test a nipple shield to help prevent HIV transmission during breastfeeding.
Female-Initiated HIV Prevention: What will we learn from upcoming trials?
A 2007 document developed in anticipation of data from the Carraguard microbicide and MIRA diaphragm trials of women-initiated prevention strategies. It contains explanations of trial design and possible outcomes.
A Cascade of Hope and Questions: Anticipating results of ARV-based HIV prevention trials
A report designed to help advocates understand results of the 2010 CAPRISA 004 trial and how they related to the research agenda for ARV-based prevention strategies.
Understanding the Results of CAPRISA 004
A 2010 document discussing the results of the CAPRISA 004 microbicide gel trial. It explores the implications of the data and outlines the next steps in evaluating tenofovir gel.
PrEP: A new option for women for safer loving
A brochure designed for women who want information on whether PrEP is the right prevention option for them.
Adherence in HIV Prevention Research: A primer for HIV prevention advocates
A two-page resource providing simple explanations of how adherence is defined and measured in biomedical HIV prevention trials, with a focus on PrEP and microbicides.
Women and Prevention Research: Designing, testing and marketing products to improve adherence
From AVAC’s Research & Reality webinar series, this recent webinar focused on essential questions about what recent trials do—and do not—tell us about whether women will want or use prevention tools including microbicide gels, rings and oral tenofovir-based PrEP.